avapro has been researched along with Cirrhosis in 21 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Excerpt | Relevance | Reference |
---|---|---|
"The aim of this study was to investigate the effect of canagliflozin (CANA) on ventricular remodeling in patients with preserved ejection fraction (HFpEF) heart failure and to further investigate its possible molecular mechanisms." | 8.31 | Canagliflozin Ameliorates Ventricular Remodeling through Apelin/Angiotensin-Converting Enzyme 2 Signaling in Heart Failure with Preserved Ejection Fraction Rats. ( Guo, Y; He, L; Ma, S; Wang, X; Wang, Y; Wang, Z; Zhai, J; Zhang, G; Zhang, T; Zuo, Q, 2023) |
"To compare the potential beneficial effects of the angiotensin converting enzyme inhibitor (ACEI) benazepril and the angiotensin II receptor 1 blocker (ARB) irbesartan on vaginal vascular remodeling and fibrosis in female spontaneously hypertensive rats (SHRs)." | 7.96 | Protective effects of irbesartan and benazepril against vaginal vascular remodeling and fibrosis in female spontaneously hypertensive rats. ( Li, N; Liang, W; Ma, R; Wang, Q; Yu, J; Yu, X; Zhao, X; Zhao, Y, 2020) |
"Angiotensin II (Ang II) can induce cardiac fibrosis, but the underlying mechanisms are incompletely understood." | 7.72 | Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. ( Belloni, AS; Kreutz, R; Nussdorfer, GG; Paul, M; Pessina, AC; Rossi, GP; Seccia, TM, 2003) |
"The aim of this study was to investigate the effect of canagliflozin (CANA) on ventricular remodeling in patients with preserved ejection fraction (HFpEF) heart failure and to further investigate its possible molecular mechanisms." | 4.31 | Canagliflozin Ameliorates Ventricular Remodeling through Apelin/Angiotensin-Converting Enzyme 2 Signaling in Heart Failure with Preserved Ejection Fraction Rats. ( Guo, Y; He, L; Ma, S; Wang, X; Wang, Y; Wang, Z; Zhai, J; Zhang, G; Zhang, T; Zuo, Q, 2023) |
"To compare the potential beneficial effects of the angiotensin converting enzyme inhibitor (ACEI) benazepril and the angiotensin II receptor 1 blocker (ARB) irbesartan on vaginal vascular remodeling and fibrosis in female spontaneously hypertensive rats (SHRs)." | 3.96 | Protective effects of irbesartan and benazepril against vaginal vascular remodeling and fibrosis in female spontaneously hypertensive rats. ( Li, N; Liang, W; Ma, R; Wang, Q; Yu, J; Yu, X; Zhao, X; Zhao, Y, 2020) |
"Angiotensin-converting enzyme 2 (ACE2), a monocarboxypeptidase which metabolizes angiotensin II (Ang II) to generate Ang-(1-7), has been shown to prevent cardiac hypertrophy and injury but the mechanism remains elusive." | 3.79 | Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice. ( Gao, PJ; Jin, HY; Lu, L; Oudit, GY; Penninger, JM; Shang, QH; Song, B; Xu, YL; Zhang, ZZ; Zhong, JC; Zhou, T; Zhu, DL, 2013) |
"In normal mice, HS diet induces septum-predominant LVH and fibrosis through activation of the cardiac RAS-ERK pathway, which can be blocked by irbesartan or ramipril, indicating a key role of the cardiac RAS in HS diet-induced LVH." | 3.76 | The cardiac renin-angiotensin system is responsible for high-salt diet-induced left ventricular hypertrophy in mice. ( Adamy, C; Berdeaux, A; Crozatier, B; Hittinger, L; Le Corvoisier, P; Michel, JB; Sambin, L; Su, J, 2010) |
"Angiotensin II (Ang II) can induce cardiac fibrosis, but the underlying mechanisms are incompletely understood." | 3.72 | Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. ( Belloni, AS; Kreutz, R; Nussdorfer, GG; Paul, M; Pessina, AC; Rossi, GP; Seccia, TM, 2003) |
"Myocardial fibrosis is a key pathological feature of HFPEF." | 2.76 | Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. ( Anand, IS; Black, M; Carson, PE; Elsik, M; Komajda, M; Krum, H; Massie, BM; McKelvie, RS; McMurray, JJ; Ptaszynska, A; Schneider, HG; Zile, MR, 2011) |
"Myocardial fibrosis is one of the serious pathological changes, so investigating the pathogenesis of myocardial fibrosis has the significant value." | 1.51 | Effect of Irbesartan on AGEs-RAGE and MMPs systems in rat type 2 diabetes myocardial-fibrosis model. ( Guanjun, Z; Heng, Z; Hongwei, Y; Jie, H; Jie, T; Junfeng, H; Qin, G; Ruiping, C; Xingyu, L; Yingyan, F; Zhenghong, L, 2019) |
"Proteinuria was markedly attenuated in the sulodexide-treated groups." | 1.38 | Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure. ( Chen, XM; Li, P; Ma, LL; Wang, JZ; Wei, RB; Xie, RJ; Xie, YS; Yin, M, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (23.81) | 29.6817 |
2010's | 12 (57.14) | 24.3611 |
2020's | 4 (19.05) | 2.80 |
Authors | Studies |
---|---|
Wang, Z | 3 |
Zhai, J | 3 |
Zhang, T | 3 |
He, L | 3 |
Ma, S | 3 |
Zuo, Q | 3 |
Zhang, G | 3 |
Wang, Y | 2 |
Guo, Y | 3 |
Wang, X | 2 |
Ma, R | 1 |
Zhao, Y | 1 |
Yu, X | 1 |
Li, N | 1 |
Wang, Q | 1 |
Liang, W | 1 |
Zhao, X | 1 |
Yu, J | 1 |
Hongwei, Y | 1 |
Ruiping, C | 1 |
Yingyan, F | 1 |
Guanjun, Z | 1 |
Jie, H | 1 |
Xingyu, L | 1 |
Jie, T | 1 |
Zhenghong, L | 1 |
Qin, G | 1 |
Junfeng, H | 1 |
Heng, Z | 1 |
Kusunoki, H | 1 |
Taniyama, Y | 1 |
Rakugi, H | 1 |
Morishita, R | 1 |
Zhang, ZZ | 1 |
Shang, QH | 1 |
Jin, HY | 1 |
Song, B | 1 |
Oudit, GY | 1 |
Lu, L | 1 |
Zhou, T | 1 |
Xu, YL | 1 |
Gao, PJ | 1 |
Zhu, DL | 1 |
Penninger, JM | 1 |
Zhong, JC | 1 |
Chen, Q | 1 |
Pang, L | 1 |
Huang, S | 1 |
Lei, W | 1 |
Huang, D | 1 |
Kataoka, N | 1 |
Nishida, K | 1 |
Kinoshita, K | 1 |
Sakamoto, T | 1 |
Nakatani, Y | 1 |
Tsujino, Y | 1 |
Mizumaki, K | 1 |
Inoue, H | 1 |
Kinugawa, K | 1 |
Seccia, TM | 2 |
Caroccia, B | 1 |
Gioco, F | 1 |
Piazza, M | 1 |
Buccella, V | 1 |
Guidolin, D | 1 |
Guerzoni, E | 1 |
Montini, B | 1 |
Petrelli, L | 1 |
Pagnin, E | 1 |
Ravarotto, V | 1 |
Belloni, AS | 2 |
Calò, LA | 1 |
Rossi, GP | 2 |
Zhao, G | 1 |
Zhao, H | 1 |
Tu, L | 1 |
Xu, X | 1 |
Zheng, C | 1 |
Jiang, M | 1 |
Wang, P | 1 |
Wang, D | 1 |
Le Corvoisier, P | 1 |
Adamy, C | 1 |
Sambin, L | 1 |
Crozatier, B | 1 |
Berdeaux, A | 1 |
Michel, JB | 1 |
Hittinger, L | 1 |
Su, J | 1 |
Tang, RN | 1 |
Lv, LL | 1 |
Zhang, JD | 1 |
Dai, HY | 1 |
Li, Q | 1 |
Zheng, M | 1 |
Ni, J | 1 |
Ma, KL | 1 |
Liu, BC | 2 |
Krum, H | 1 |
Elsik, M | 1 |
Schneider, HG | 1 |
Ptaszynska, A | 1 |
Black, M | 1 |
Carson, PE | 1 |
Komajda, M | 1 |
Massie, BM | 1 |
McKelvie, RS | 1 |
McMurray, JJ | 1 |
Zile, MR | 1 |
Anand, IS | 1 |
Li, P | 1 |
Ma, LL | 1 |
Xie, RJ | 1 |
Xie, YS | 1 |
Wei, RB | 1 |
Yin, M | 1 |
Wang, JZ | 1 |
Chen, XM | 1 |
Marut, W | 1 |
Kavian, N | 1 |
Servettaz, A | 1 |
Hua-Huy, T | 1 |
Nicco, C | 1 |
Chéreau, C | 1 |
Weill, B | 1 |
Dinh-Xuan, AT | 1 |
Batteux, F | 1 |
Kreutz, R | 1 |
Paul, M | 1 |
Nussdorfer, GG | 1 |
Pessina, AC | 1 |
Müller-Brunotte, R | 1 |
Kahan, T | 1 |
López, B | 1 |
Edner, M | 1 |
González, A | 1 |
Díez, J | 1 |
Malmqvist, K | 1 |
Xia, HL | 1 |
Wu, JN | 1 |
Zhang, XL | 1 |
Liu, DG | 1 |
Gong, YX | 1 |
Zhou, A | 1 |
Yu, L | 1 |
Li, J | 1 |
Zhang, J | 1 |
Wang, H | 1 |
Gervais, M | 1 |
Fornes, P | 1 |
Richer, C | 1 |
Nisato, D | 1 |
Giudicelli, JF | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)[NCT00095238] | Phase 3 | 4,128 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
Randomized, Double-blind Evaluation of the Effects of Irbesartan and Atenolol on Cardiovascular Structure and Function in Subjects With Hypertension and Left Ventricular Hypertrophy[NCT00389168] | Phase 2/Phase 3 | 115 participants (Actual) | Interventional | 1995-04-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Adjusted ratio to baseline in geometric mean in Pro-BNP in the blood. Ratio to Baseline = On-therapy geometric mean divided by baseline geometric mean. A lower score signifies improvement. Change from baseline adjusted for baseline value and angiotensin converting enzyme inhibitor use at baseline. Analysis uses natural logarithms of excretion rate values. (NCT00095238)
Timeframe: Baseline, Month 6, Month 14
Intervention | pg/mL (Geometric Mean) |
---|---|
Placebo - Month 6 | 0.98 |
Irbesartan - Month 6 | 0.93 |
Placebo - Month 14 | 1.00 |
Irbesartan - Month 14 | 1.01 |
NYHA functional classification=4-tiered system relating symptoms to everyday activities & quality of life. (See Reporting Groups for description of each class.) Change of NYHA functional class from baseline was grouped into 3 categories: improved, unchanged, or worsened (based on case report form [CRF] assessment). If a post-randomization CRF assessment was missing or participant died, was hospitalized for worsening heart failure or discontinued study medication for worsening heart failure, the participant was classified as Major Event. (NCT00095238)
Timeframe: Baseline, Month 6, Month 10, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years.
Intervention | participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Month 6 - Improved | Month 6 - Unchanged | Month 6 - Worsened | Month 6 - Major Event | Month 6 - No Data | Month 10 - Improved | Month 10 - Unchanged | Month 10 - Worsened | Month 10 - Major Event | Month 10 - No Data | Month 14 - Improved | Month 14 - Unchanged | Month 14 - Worsened | Month 14 - Major Event | Month 14 - No Data | Final Visit - Improved | Final Visit - Unchanged | Final Visit - Worsened | Final Visit - Major Event | Final Visit - No Data | |
Irbesartan Baseline All Classes Combined | 936 | 966 | 48 | 10 | 107 | 948 | 911 | 58 | 41 | 109 | 933 | 866 | 61 | 75 | 132 | 928 | 658 | 97 | 324 | 60 |
Irbesartan Baseline Class I or II | 55 | 310 | 41 | 2 | 18 | 44 | 294 | 53 | 10 | 25 | 38 | 287 | 50 | 22 | 29 | 42 | 230 | 68 | 75 | 11 |
Irbesartan Class III or IV | 881 | 656 | 7 | 8 | 89 | 904 | 617 | 5 | 31 | 84 | 895 | 579 | 11 | 53 | 103 | 886 | 428 | 29 | 249 | 49 |
Placebo Baseline All Classes Combined | 881 | 1016 | 51 | 14 | 98 | 902 | 939 | 71 | 42 | 106 | 902 | 890 | 69 | 80 | 119 | 882 | 694 | 107 | 320 | 57 |
Placebo Baseline Class I or II | 47 | 338 | 47 | 2 | 11 | 42 | 317 | 63 | 9 | 14 | 39 | 312 | 62 | 16 | 16 | 42 | 254 | 78 | 66 | 5 |
Placebo Class III or IV | 834 | 678 | 4 | 12 | 87 | 860 | 622 | 8 | 33 | 92 | 863 | 578 | 7 | 64 | 103 | 840 | 440 | 29 | 254 | 52 |
Based on the Cockcroft-Gault formula calculation, a commonly used surrogate marker to estimate creatinine clearance, which in turn is an approximate measure of GFR. It employs serum creatinine measurements and a patient's weight to predict the creatinine clearance. Adjusted for baseline GFR and angiotensin-converting enzyme inhibitor use at baseline (ACE-I). A decrease from baseline signifies worsening. The adjusted mean change from baseline value is from the model (calculated prior to rounding), whereas the other two points are the baseline mean and post mean. (NCT00095238)
Timeframe: Baseline, Month 6, Month 18, Month 30
Intervention | mL/min/1.73m2 (Mean) | ||
---|---|---|---|
Baseline Mean | Post-Baseline Mean | Adjusted Mean Change | |
Irbesartan - Month 18 | 73.49 | 68.00 | -5.50 |
Irbesartan - Month 30 | 74.37 | 67.05 | -7.12 |
Irbesartan - Month 6 | 73.13 | 69.21 | -3.91 |
Placebo - Month 18 | 73.58 | 70.88 | -2.69 |
Placebo - Month 30 | 73.34 | 69.51 | -4.02 |
Placebo - Month 6 | 73.02 | 71.97 | -1.07 |
Based on the Cockcroft-Gault formula calculation, a commonly used surrogate marker to estimate creatinine clearance, which in turn is an approximate measure of GFR. It employs serum creatinine measurements and a patient's weight to predict the creatinine clearance. Adjusted for baseline GFR and angiotensin-converting enzyme inhibitor use at baseline (ACE-I). A decrease from baseline signifies worsening. The adjusted mean change from baseline value is from the model (calculated prior to rounding), whereas the other two points are the baseline mean and post mean. (NCT00095238)
Timeframe: Baseline, Month 42, Month 54, Month 66
Intervention | mL/min/1.73m2 (Mean) | ||
---|---|---|---|
Baseline Mean | Post-Baseline Mean | Adjusted Mean Change | |
Irbesartan - Month 42 | 74.95 | 67.48 | -7.36 |
Irbesartan - Month 54 | 75.17 | 68.24 | -6.93 |
Irbesartan - Month 66 | 71.84 | 64.85 | -5.46 |
Placebo - Month 42 | 74.37 | 71.34 | -3.14 |
Placebo - Month 54 | 75.29 | 72.65 | -2.63 |
Placebo - Month 66 | 63.47 | 60.09 | -4.91 |
Mean score at baseline and final visit in Minnesota Living with Heart Failure (MLWHF) questionnaire, a 21-item, patient-reported, 6-point (ranging from 0-5; higher score=poorer quality of life; highest possible score=105) measurement of quality of life in persons with heart failure. (NCT00095238)
Timeframe: Baseline, Final Visit=last scheduled visit specified in the protocol at conclusion of the entire study by the sponsor. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years.
Intervention | units on a scale (Mean) | |
---|---|---|
Baseline Mean | Final Visit Mean | |
Irbesartan - Final Visit | 38.9 | 38.3 |
Placebo - Final Visit | 42.5 | 42.6 |
Mean score and adjusted mean change from baseline in Minnesota Living with Heart Failure (MLWHF) questionnaire, a 21-item, patient-reported, 6-point (ranging from 0-5; higher score=poorer quality of life; highest possible score=105) measurement of quality of life in persons with heart failure. (NCT00095238)
Timeframe: Baseline, Month 6, Month 14
Intervention | units on a scale (Mean) | ||
---|---|---|---|
Baseline Mean Score | Mean Score at Timepoint | Adjusted Mean Change from Baseline | |
Irbesartan - Month 14 | 42.8 | 32.1 | -10.6 |
Irbesartan - Month 6 | 43.0 | 33.2 | -9.8 |
Placebo - Month 14 | 42.7 | 31.6 | -11.2 |
Placebo - Month 6 | 42.7 | 32.9 | -10.0 |
Frequency of new onset AF in participants with no prior AF history or evidence of AF on baseline ECG. Stratified by use of angiotensin-converting enzyme (ACE) inhibitors and measured by adverse events reporting and final ECG recording read by the investigator. (NCT00095238)
Timeframe: Baseline, Final Visit
Intervention | participants (Number) | |
---|---|---|
No prior AF history or Evidence on Baseline ECG | Participants with New Onset Atrial Fibrillation | |
Irbesartan + ACE-I Use | 366 | 35 |
Irbesartan no ACE-I Use | 1089 | 103 |
Placebo + ACE-I Use | 344 | 29 |
Placebo no ACE-I Use | 1102 | 99 |
Assessments are directly based on the Case Report Form (CRF). If the post-randomization CRF assessment was missing and the subject died, was hospitalized for worsening heart failure, or discontinued study medication for worsening heart failure, the subject was considered as having a Major Event. Participants who are summarized under Major Events are categorized as Worsened Markedly. (NCT00095238)
Timeframe: Baseline, Month 6, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years.
Intervention | Participants (Number) | ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Month 6 - Improved Markedly | Month 6 - Improved Moderately | Month 6 - Improved Slightly | Month 6 - Unchanged | Month 6 - Worsened Slightly | Month 6 - Worsened Moderately | Month 6 - Worsened Markedly | Month 6 - Major Event | Month 6 - No Data | Month 14 - Improved Markedly | Month 14 - Improved Moderately | Month 14 - Improved Slightly | Month 14 - Unchanged | Month 14 - Worsened Slightly | Month 14 - Worsened Moderately | Month 14 - Worsened Markedly | Month 14 - Major Event | Month 14 - No Data | Final Visit - Improved Markedly | Final Visit - Improved Moderately | Final Visit - Improved Slightly | Final Visit - Unchanged | Final Visit - Worsened Slightly | Final Visit - Worsened Moderately | Final Visit - Worsened Markedly | Final Visit - Major Event | Final Visit - No Data | |
Irbesartan | 255 | 549 | 512 | 508 | 83 | 22 | 9 | 8 | 121 | 247 | 519 | 460 | 476 | 103 | 28 | 13 | 68 | 153 | 213 | 382 | 328 | 460 | 114 | 64 | 35 | 395 | 76 |
Placebo | 276 | 536 | 501 | 510 | 83 | 22 | 10 | 7 | 116 | 232 | 531 | 430 | 509 | 90 | 39 | 10 | 74 | 146 | 212 | 339 | 335 | 461 | 145 | 75 | 32 | 384 | 78 |
Assessments are directly based on the Case Report Form (CRF). If the post-randomization CRF assessment was missing and the subject died, was hospitalized for worsening heart failure, or discontinued study medication for worsening heart failure, the subject was considered as having a Major Event. Participants who are summarized under Major Events are categorized as Worsened Markedly. (NCT00095238)
Timeframe: Baseline, Month 6, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years.
Intervention | Participants (Number) | ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Month 6 - Improved Markedly | Month 6 - Improved Moderately | Month 6 - Improved Slightly | Month 6 - Unchanged | Month 6 - Worsened Slightly | Month 6 - Worsened Moderately | Month 6 - Worsened Markedly | Month 6 - Major Event | Month 6 - No Data | Month 14 - Improved Markedly | Month 14 - Improved Moderately | Month 14 - Improved Slightly | Month 14 - Unchanged | Month 14 - Worsened Slightly | Month 14 - Worsened Moderately | Month 14 - Worsened Markedly | Month 14 - Major Event | Month 14 - No Data | Final Visit - Improved Markedly | Final Visit - Improved Moderately | Final Visit - Improved Slightly | Final Visit - Unchanged | Final Visit - Worsened Slightly | Final Visit - Worsened Moderately | Final Visit - Worsened Markedly | Final Visit - Major Event | Final Visit - No Data | |
Irbesartan | 193 | 523 | 504 | 579 | 97 | 28 | 13 | 8 | 122 | 195 | 513 | 439 | 525 | 115 | 48 | 11 | 68 | 153 | 157 | 361 | 319 | 479 | 166 | 80 | 34 | 395 | 76 |
Placebo | 200 | 519 | 471 | 596 | 101 | 38 | 13 | 7 | 116 | 182 | 489 | 443 | 559 | 109 | 43 | 16 | 74 | 146 | 178 | 300 | 337 | 477 | 176 | 90 | 42 | 383 | 78 |
Assessments are directly based on the Case Report Form (CRF). If the post-randomization CRF assessment was missing and the subject died, was hospitalized for worsening heart failure, or discontinued study medication for worsening heart failure, the subject was considered as having a Major Event. Participants who are summarized under Major Events are categorized as Worsened Markedly. (NCT00095238)
Timeframe: Baseline, Month 6, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years.
Intervention | Participants (Number) | ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Month 6 - Improved Markedly | Month 6 - Improved Moderately | Month 6 - Improved Slightly | Month 6 - Unchanged | Month 6 - Worsened Slightly | Month 6 - Worsened Moderately | Month 6 - Worsened Markedly | Month 6 - Major Event | Month 6 - No Data | Month 14 - Improved Markedly | Month 14 - Improved Moderately | Month 14 - Improved Slightly | Month 14 - Unchanged | Month 14 - Worsened Slightly | Month 14 - Worsened Moderately | Month 14 - Worsened Markedly | Month 14 - Major Event | Month 14 - No Data | Final Visit - Improved Markedly | Final Visit - Improved Moderately | Final Visit - Improved Slightly | Final Visit - Unchanged | Final Visit - Worsened Slightly | Final Visit - Worsened Moderately | Final Visit - Worsened Markedly | Final Visit - Major Event | Final Event - No Data | |
Irbesartan | 235 | 552 | 529 | 537 | 63 | 13 | 8 | 8 | 122 | 234 | 532 | 461 | 503 | 78 | 30 | 8 | 68 | 153 | 207 | 378 | 332 | 480 | 121 | 52 | 25 | 396 | 76 |
Placebo | 230 | 563 | 519 | 529 | 69 | 20 | 8 | 7 | 116 | 206 | 534 | 450 | 527 | 82 | 35 | 7 | 74 | 146 | 201 | 339 | 352 | 495 | 109 | 76 | 28 | 383 | 78 |
Treatment comparisons for time to all-cause death (NCT00095238)
Timeframe: Year 1, Year 2, Year 3, Year 4, Year 5
Intervention | percentage of participants (Number) | ||||
---|---|---|---|---|---|
Percentage at 1 Year | Percentage at 2 Years | Percentage at 3 Years | Percentage at 4 Years | Percentage at 5 Years | |
Irbesartan | 4.1 | 8.1 | 12.8 | 17.9 | 25.0 |
Placebo | 3.8 | 8.6 | 13.8 | 18.5 | 23.6 |
Treatment comparisons for time to cardiovascular death (NCT00095238)
Timeframe: Year 1, Year 2, Year 3, Year 4, Year 5
Intervention | percentage of participants (Number) | ||||
---|---|---|---|---|---|
Percentage 1 Year | Percentage 2 Years | Percentage 3 Years | Percentage at 4 Years | Percentage at 5 Years | |
Irbesartan | 3.3 | 6.2 | 9.6 | 13.0 | 18.0 |
Placebo | 3.0 | 6.5 | 10.0 | 13.1 | 17.1 |
Treatment comparisons for time to CV death or CV hospitalization. Protocol-specified CV hospitalizations include hospitalizations ≥24 hrs or involve a calendar date change for a primary cause of worsening heart failure, unstable angina, myocardial infarction, ventricular dysrhythmia, atrial dysrhythmia or stroke that also requires intravenous or intramuscular therapy or a related procedure or significant augmentation of oral therapy. Protocol specified CV hospitalizations also include myocardial infarction or stroke occurring during any hospitalization. (NCT00095238)
Timeframe: Year 1, Year 2, Year 3, Year 4, Year 5
Intervention | percentage of participants (Number) | ||||
---|---|---|---|---|---|
Percentage at 1 Year | Percentage at 2 Years | Percentage at 3 Years | Percentage at 4 Years | Percentage at 5 Years | |
Irbesartan | 11.6 | 19.2 | 24.2 | 30.0 | 35.0 |
Placebo | 11.4 | 20.0 | 25.8 | 30.9 | 35.8 |
Treatment comparisons for time to cardiovascular death, non-fatal MI, or non-fatal stroke. (NCT00095238)
Timeframe: Year 1, Year 2, Year 3, Year 4, Year 5
Intervention | percentage of participants (Number) | ||||
---|---|---|---|---|---|
Percentage at 1 Year | Percentage at 2 Years | Percentage at 3 Years | Percentage at 4 Years | Percentage at 5 Years | |
Irbesartan | 5.2 | 8.7 | 12.9 | 17.2 | 23.0 |
Placebo | 4.2 | 9.3 | 13.6 | 17.6 | 22.4 |
Treatment comparisons for time to heart failure mortality or heart failure hospitalization (NCT00095238)
Timeframe: Year 1, Year 2, Year 3, Year 4, Year 5
Intervention | percentage of participants (Number) | ||||
---|---|---|---|---|---|
Percentage at 1 Year | Percentage at 2 Years | Percentage at 3 Years | Percentage at 4 Years | Percentage at 5 Years | |
Irbesartan | 7.9 | 12.9 | 15.7 | 19.8 | 23.6 |
Placebo | 8.2 | 13.7 | 17.2 | 20.3 | 23.8 |
Treatment comparisons for time to protocol-specified CV hospitalization. Protocol-specified CV hospitalizations include hospitalizations ≥24 hrs or involve a calendar date change for a primary cause of worsening heart failure, unstable angina, myocardial infarction, ventricular dysrhythmia, atrial dysrhythmia or stroke that also requires intravenous or intramuscular therapy or a related procedure or significant augmentation of oral therapy. Protocol specified CV hospitalizations also include myocardial infarction or stroke occurring during any hospitalization. (NCT00095238)
Timeframe: Year 1, Year 2, Year 3, Year 4, Year 5
Intervention | percentage of participants (Number) | ||||
---|---|---|---|---|---|
Percentage at 1 Year | Percentage at 2 Years | Percentage at 3 Years | Percentage at 4 Years | Percentage at 5 Years | |
Irbesartan | 9.7 | 16.3 | 20.5 | 24.8 | 28.5 |
Placebo | 9.8 | 17.1 | 21.7 | 25.9 | 29.0 |
Treatment comparisons for time to first occurrence of composite outcome of all-cause death (composite outcome of death) or protocol-specified CV hospitalization. Protocol-specified CV hospitalizations include those ≥24 hrs or involving a calendar date change for a primary cause of worsening heart failure, unstable angina, myocardial infarction, ventricular or atrial dysrhythmia, or stroke, that also require intravenous or intramuscular therapy or a related procedure or significant augmentation of oral therapy. In addition, MI or stroke during any hospitalization are included. (NCT00095238)
Timeframe: Year 1, Year 2, Year 3, Year 4, Year 5
Intervention | percentage of participants (Number) | ||||
---|---|---|---|---|---|
Percentage at 1 Year | Percentage at 2 Years | Percentage at 3 Years | Percentage at 4 Years | Percentage at 5 Years | |
Irbesartan | 12.3 | 20.7 | 26.4 | 32.9 | 39.2 |
Placebo | 12.1 | 21.3 | 28.4 | 34.2 | 39.5 |
Treatment comparisons for time to new onset of diabetes (from adverse event reporting) among subjects with no prior history of diabetes. (NCT00095238)
Timeframe: Year 1, Year 2, Year 3, Year 4, Year 5
Intervention | percentage of participants (Number) | ||||
---|---|---|---|---|---|
Percentage at 1 Year | Percentage at 2 Years | Percentage at 3 Years | Percentage at 4 Years | Percentage at 5 Years | |
Irbesartan | 0.7 | 2.1 | 3.1 | 4.6 | 5.2 |
Placebo | 1.2 | 2.8 | 3.9 | 5.4 | 6.2 |
This was an assessment of the change in overall physician opinion of change from baseline status. Assessments are directly based on the Case Report Form (CRF). If the post-randomization CRF assessment was missing and the subject died, was hospitalized for worsening heart failure, or discontinued study medication for worsening heart failure, the subject was considered as having a Major Event. Participants who are summarized under Major Events are categorized as Worsened Markedly. (NCT00095238)
Timeframe: Baseline, Month 6, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years.
Intervention | participants (Number) | ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Month 6 - Improved Markedly | Month 6 - Improved Moderately | Month 6 - Improved Slightly | Month 6 - Unchanged | Month 6 - Worsened Slightly | Month 6 - Worsened Moderately | Month 6 - Worsened Markedly | Month 6 - Major Event | Month 6 - No Data | Month 14 - Improved Markedly | Month 14 - Improved Moderately | Month 14 - Improved Slightly | Month 14 - Unchanged | Month 14 - Worsened Slightly | Month 14 - Worsened Moderately | Month 14 - Worsened Markedly | Month 14 - Major Event | Month 14 - No Data | Final Visit - Improved Markedly | Final Visit - Improved Moderately | Final Visit - Improved Slightly | Final Visit - Unchanged | Final Visit - Worsened Slightly | Final Visit - Worsened Moderately | Final Visit - Worsened Markedly | Final Visit - Major Event | Final Visit - No Data | |
Irbesartan | 230 | 562 | 533 | 528 | 60 | 17 | 0 | 8 | 129 | 214 | 546 | 442 | 507 | 72 | 21 | 5 | 75 | 185 | 180 | 430 | 344 | 477 | 117 | 41 | 23 | 364 | 91 |
Placebo | 198 | 575 | 529 | 541 | 58 | 16 | 4 | 8 | 132 | 195 | 537 | 435 | 548 | 73 | 19 | 6 | 79 | 169 | 186 | 367 | 361 | 504 | 117 | 56 | 28 | 350 | 92 |
Difference in Diastolic Blood Pressure. Repeated measures multivariable analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks (NCT00389168)
Timeframe: Baseline to 48 weeks
Intervention | mm Hg (Mean) |
---|---|
Atenolol | -16.3 |
Irbesartan | -18.8 |
Changes in common carotid artery intima-media thickness, assessed by ultrasonography. (NCT00389168)
Timeframe: Baseline to 48 weeks
Intervention | mm (Mean) |
---|---|
Atenolol | 0.03 |
Irbesartan | -0.01 |
Safety was assessed by non-directed questions, and all observed and volunteered adverse events were recorded at each study visit. Serious adverse events were defined by, and reported according to the regulations of good clinical practice (GCP). none were considered related to the study medication. (NCT00389168)
Timeframe: Treatment period was baseline to 48 weeks
Intervention | Participants (Number) |
---|---|
Atenolol | 5 |
Irbesartan | 5 |
Repeated measures multivariate analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks. Data are presented as left ventricular mass in gram (g) indexed for body mass index (in m^2). (NCT00389168)
Timeframe: Baseline and 48 weeks
Intervention | g/m^2 (Mean) | ||
---|---|---|---|
12 weeks | 24 weeks | 48 weeks | |
Atenolol | -1 | -6 | -14 |
Irbesartan | -9 | -14 | -26 |
Venous plasma concentrations of angiotensin II were measured in order to study the possible associations between the activity of the renin-angiotensin-aldosteone system and changes in left ventricular mass. Further analyses of other components of the renin-angiotensin-aldosterone system and of other hormonal system (e.g. the sympathetic nervous system) have also been performed and published. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Data were log-transformed to avoid skewness before statistical evaluation. However, tabular data are given as mean values with 95% confidence to improve readability. (NCT00389168)
Timeframe: Baseline to 48 weeks
Intervention | pmol/L (Mean) | ||
---|---|---|---|
Weel 12 | Week 24 | Week 48 | |
Atenolol | -1.0 | -0.8 | -0.2 |
Irbesartan | 3.0 | 3.3 | 10.0 |
Changes in left ventricular diastolic function from baseline to week 48 will be evaluated as the difference in E/A ratio. Conventional pulsed wave Doppler echocardiography was used for recordings of mitral inflow in. The peak of early (E) and late (A) mitral flow velocities were measured, and the E/A-ratio was calculated. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Some echocardiographic recordings at some time point may be of insufficient quality or missing, and the number of observations may not always correspond to the total number of participants at all time points. (NCT00389168)
Timeframe: Baseline to 48 weeks
Intervention | ratio (Mean) | ||
---|---|---|---|
Week 12 | Week 24 | Week 48 | |
Atenolol | 0.18 | 0.16 | 0.13 |
Irbesartan | 0.10 | 0.04 | 0.10 |
2 trials available for avapro and Cirrhosis
Article | Year |
---|---|
Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Collagen; Double-Blin | 2011 |
Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive | 2007 |
19 other studies available for avapro and Cirrhosis
Article | Year |
---|---|
Canagliflozin ameliorates epithelial-mesenchymal transition in high-salt diet-induced hypertensive renal injury through restoration of sirtuin 3 expression and the reduction of oxidative stress.
Topics: Animals; Canagliflozin; Catalase; Diet; Epithelial-Mesenchymal Transition; Fibrosis; Humans; Hyperte | 2023 |
Canagliflozin Ameliorates Ventricular Remodeling through Apelin/Angiotensin-Converting Enzyme 2 Signaling in Heart Failure with Preserved Ejection Fraction Rats.
Topics: Angiotensin-Converting Enzyme 2; Animals; Apelin; Canagliflozin; Fibrosis; Heart Failure; Humans; Ir | 2023 |
Canagliflozin and irbesartan ameliorate renal fibrosis via the TGF-β1/Smad signaling pathway in Dahl salt-sensitive rats.
Topics: Animals; Blood Pressure; Canagliflozin; Fibrosis; Hypertension; Irbesartan; Kidney; Kidney Diseases; | 2023 |
Protective effects of irbesartan and benazepril against vaginal vascular remodeling and fibrosis in female spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; B | 2020 |
Effect of Irbesartan on AGEs-RAGE and MMPs systems in rat type 2 diabetes myocardial-fibrosis model.
Topics: Animals; Blood Glucose; Body Weight; Collagen; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; | 2019 |
Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Disease Models, Animal; Epithe | 2013 |
Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Biphenyl Compounds; Cardiom | 2013 |
Effects of emodin and irbesartan on ventricular fibrosis in Goldblatt hypertensive rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blotting, West | 2014 |
Effect of irbesartan on development of atrial fibrosis and atrial fibrillation in a canine atrial tachycardia model with left ventricular dysfunction, association with p53.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Atrial Remodeling; Biphenyl C | 2016 |
Endothelin-1 Drives Epithelial-Mesenchymal Transition in Hypertensive Nephroangiosclerosis.
Topics: Actins; Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; Biphenyl Compounds | 2016 |
Effects and mechanism of irbesartan on tubulointerstitial fibrosis in 5/6 nephrectomized rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Fibrosis; Irbesartan; Kidney D | 2010 |
The cardiac renin-angiotensin system is responsible for high-salt diet-induced left ventricular hypertrophy in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Autoradi | 2010 |
Effects of angiotensin II receptor blocker on myocardial endothelial-to-mesenchymal transition in diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blotting, Western; Calcium-Bin | 2013 |
Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Biphenyl Compounds; Blood Pressure; Bl | 2012 |
Amelioration of systemic fibrosis in mice by angiotensin II receptor blockade.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Biphenyl Compoun | 2013 |
Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II.
Topics: Angiotensin II; Animals; Animals, Genetically Modified; Antihypertensive Agents; Biphenyl Compounds; | 2003 |
Influence of irbesartan on expression of ILK and its relationship with epithelial-mesenchymal transition in mice with unilateral ureteral obstruction.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cadherins; Cell Transd | 2007 |
Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compou | 2000 |
Effects of angiotensin II AT1-receptor blockade on coronary dynamics, function, and structure in postischemic heart failure in rats.
Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Coronary Vessels; Dose-Response Relat | 2000 |